empagliflozin 5 MG / linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG 24HR Extended Release Oral Tablet
- RxCUI
- 2359356
- RxNorm name
- empagliflozin 5 MG / linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG 24HR Extended Release Oral Tablet
- Display name
- empagliflozin 5 MG / linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG 24HR Extended Release Oral Tablet
- Full name
- empagliflozin 5 MG / linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG 24HR Extended Release Oral Tablet
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:03
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Trijardy XR | EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 71873567-9594-452a-bb92-34a129adecac | 2026-01-30 | Boxed warning, Warnings, Adverse reactions | 2359356 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 71873567-9594-452a-bb92-34a129adecac | empagliflozin 5 MG / linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG 24HR Extended Release Oral Tablet | PSN | 10 | These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2020 | 20260130 |
| 71873567-9594-452a-bb92-34a129adecac | 24 HR empagliflozin 5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet | SCD | 10 | These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2020 | 20260130 |